Metabolic & Incretin Research blend
Tirzepatide + LY TLY40
Incretin + amylin-type blend
Research blend of tirzepatide, a GIP and GLP-1 dual agonist, with an amylin-type compound whose identity is to be confirmed.
Evidence level. Little or no public data, or the exact identity is still being confirmed. For a blend, the rating covers the combination itself; each component has its own profile. About the badges
- Class
- Incretin + amylin-type blend
- Category
- Metabolic & Incretin
- Type
- Research blend
- Abbreviation
- TLY40
- Development and regulatory status
- Status not confirmed
Blend composition
Tirzepatide 30 mg + LY 10 mg
Each component is profiled separately in the catalogue: Tirzepatide, Eloralintide.
What researchers study
Blend label pairs tirzepatide, a GIP/GLP-1 dual agonist, with 'LY', described as an amylin-type compound. The catalogue abbreviation LY corresponds to eloralintide, a Lilly amylin receptor agonist, but the identity is to be confirmed by Novatide.
Research areas
- Combined incretin and amylin-type signalling studies
- Comparing single and combined receptor pathways
- Appetite and energy-balance signalling in models
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- literature check
No published studies of tirzepatide combined with an LY or eloralintide partner were identified
- phase 2 trial
Eloralintide, the likely LY compound: mean weight change at 48 weeks was -20.1% (efficacy estimand) in the top-dose group versus -0.4% with placebo
- phase 3 trial
Tirzepatide alone: mean weight change at 72 weeks ranged from -15% to -20.9% across dose groups versus -3.1% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- TirzepatideGIP/GLP-1 dual agonist, a component of this blend
- Eloralintideamylin receptor agonist, presumed identity of the LY component
